Composite fatty acid ether amides suppress growth of liver cancer cells in vitro and in an in vivo allograft mouse model

Cellular Oncology

Volumn 36, Issue 3, 2013, Pages 247-257

  Cao, Mengde ^a   Prima, Victor ^a   Nelson, David ^b   Svetlov, Stanislav ^a,c  

^a Banyan Laboratories Inc   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

AKT; Alkyl (alkenyl)oxy isopropylamino propanol (AIP); Apoptosis; Autophagy; beta spectrin; Hepatocellular carcinoma (HCC); Tumor allograft

Indexed keywords

[1 [(1 BENZYL 3 CYCLOPROPYLAMINO 2,3 DIOXOPROPYL)CARBAMOYL] 3 METHYLBUTYL]CARBAMIC ACID 2 (2 METHOXYETHOXY)ETHYL ESTER; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 9; FATTY ACID DERIVATIVE; PROTEIN KINASE B BETA; SPECTRIN; SPHINGOSINE KINASE 2;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INCIDENCE; CANCER INHIBITION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL VIABILITY; CHEMICAL STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUMOR GROWTH;

AMIDES; ANIMALS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL-FREE SYSTEM; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ETHER; FATTY ACIDS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTEOLYSIS; SPECTRIN; SPHEROIDS, CELLULAR;

EID: 84878548476     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-013-0132-x     Document Type: Article

References (40)

1. G.J. Prud'homme, Cancer stem cells and novel targets for antitumor strategies. Curr. Pharm. Des. 18, 2838-2849 (2012)
2. B.A. Grotenhuis, B.P. Wijnhoven, J.J. van Lanschot, Cancer stem cells and their potential implications for the treatment of solid tumors. J. Surg. Oncol. 106, 209-215 (2012)
3. C.M. Tong, S. Ma, X.Y. Guan, Biology of hepatic cancer stem cells. J. Gastroenterol. Hepatol. 26, 1229-1237 (2011)
4. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, Estimating the world cancer burden: Globocan, 2000. Int. J. Cancer 94, 153-156 (2001)
5. F.X. Bosch, J. Ribes, M. Diaz, R. Cleries, Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5-S16 (2004)
6. J.M. Llovet, A. Burroughs, J. Bruix, Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003)
7. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Häussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix, SHARP Investigators Study Group, Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008)
8. C.H. Yang, W.C. Lin, C.K. Chuang, Y.C. Chang, S.T. Pang, Y.C. Lin, T.T. Kuo, J.J. Hsieh, J.W. Chang, Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br. J. Dermatol. 158, 592-596 (2008)
9. M. Cao, Y. Xu, J.I. Youn, R. Cabrera, X. Zhang, D. Gabrilovich, D.R. Nelson, C. Liu, Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest. 91, 598-608 (2011)
10. N. Oishi, X.W. Wang, Novel therapeutic strategies for targeting liver cancer stem cells. Int. J. Biol. Sci. 7, 517-535 (2011)
11. T. Klonisch, E. Wiechec, S. Hombach-Klonisch, S.R. Ande, S. Wesselborg, K. Schulze-Osthoff, M. Los, Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 14, 450-460 (2008)
12. D. Dingli, F. Michor, Successful therapy must eradicate cancer stem cells. Stem Cells 24, 2603-2610 (2006)
13. L. Gossage, T. Eisen, Targeting multiple kinase pathways: a change in paradigm. Clin. Cancer Res. 16, 1973-1978 (2010)
14. X. Zhao, O.O. Ogunwobi, C. Liu, Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PLoS One 6, e21980 (2011)
15. H.J. Baek, S.C. Lim, K. Kitisin, W. Jogunoori, Y. Tang, M.B. Marshall, B. Mishra, T.H. Kim, K.H. Cho, S.S. Kim, L. Mishra, Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology 48, 1128-1137 (2008)
16. Y. Tang, K. Kitisin, W. Jogunoori, C. Li, C.X. Deng, S.C. Mueller, H.W. Ressom, A. Rashid, A.R. He, J.S. Mendelson, J.M. Jessup, K. Shetty, M. Zasloff, B. Mishra, E.P. Reddy, L. Johnson, L. Mishra, Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc. Natl. Acad. Sci. U. S. A. 105, 2445-2450 (2008)
17. Z. Wang, F. Liu, W. Tu, Y. Chang, J. Yao, W. Wu, X. Jiang, X. He, J. Lin, Y. Song, Embryonic liver fodrin involved in hepatic stellate cell activation and formation of regenerative nodule in liver cirrhosis. J. Cell Mol. Med. 16, 118-128 (2012)
18. P. Rougier, E. Mitry, J.C. Barbare, J. Taieb, Hepatocellular carcinoma (HCC): an update. Semin. Oncol. 34, S12-S20 (2007)
19. C.T. Jordan, M.L. Guzman, M. Noble, Cancer stem cells. N. Engl. J. Med. 355, 1253-1261 (2006)
20. T. Chiba, Y.W. Zheng, K. Kita, O. Yokosuka, H. Saisho, M. Onodera, H. Miyoshi, M. Nakano, Y. Zen, Y. Nakanuma, H. Nakauchi, A. Iwama, H. Taniguchi, Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 133, 937-950 (2007)
21. I.M. Ghobrial, T.E. Witzig, A.A. Adjei, Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194 (2005)
22. A.M. Senderowicz, Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr. Opin. Cell Biol. 16, 670-678 (2004)
23. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, J.S. Kim, R. Luo, J. Feng, S. Ye, T.S. Yang, J. Xu, Y. Sun, H. Liang, J. Liu, J. Wang, W.Y. Tak, H. Pan, K. Burock, J. Zou, D. Voliotis, Z. Guan, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009)
24. P.T. Bhaskar, N. Hay, The two TORCs and Akt. Dev Cell 12, 487-502 (2007)
25. M. Osaki, M. Oshimura, H. Ito, PI3 K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667-676 (2004)
26. S. Peroukides, V. Bravou, A. Alexopoulos, J. Varakis, H. Kalofonos, H. Papadaki, Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol. Histopathol. 25, 299-307 (2010)
27. M. Montorsi, M. Maggioni, M. Falleni, C. Pellegrini, M. Donadon, G. Torzilli, R. Santambrogio, A. Spinelli, G. Coggi, S. Bosari, Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 54, 2040-2044 (2007)
28. P. Li, Q. Du, Z. Cao, Z. Guo, J. Evankovich, W. Yan, Y. Chang, L. Shao, D.B. Stolz, A. Tsung, D.A. Geller, Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett. 314, 213-222 (2012)
29. K.K. Wang, R. Posmantur, R. Nath, K. McGinnis, M. Whitton, R.V. Talanian, S.B. Glantz, J.S. Morrow, Simultaneous degradation of alpha II- and beta II-spectrin by caspase 3 (CPP32) in apoptotic cells. J. Biol. Chem. 273, 22490-22497 (1998)
30. N.N. Danial, S.J. Korsmeyer, Cell death: critical control points. Cell 116, 205-219 (2004)
31. S. Pattingre, A. Tassa, X. Qu, R. Garuti, X.H. Liang, N. Mizushima, M. Packer, M.D. Schneider, B. Levine, Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122, 927-939 (2005)
32. L. Wang, C. Yu, Y. Lu, P. He, J. Guo, C. Zhang, Q. Song, D. Ma, T. Shi, Y. Chen, TMEM166, a novel transmembrane protein, regulates cell autophagy and apoptosis. Apoptosis 12, 1489-1502 (2007)
33. A. Shamas-Din, H. Brahmbhatt, B. Leber, D.W. Andrews, BH3-only proteins: orchestrators of apoptosis. Biochim. Biophys. Acta 1813, 508-520 (2011)
34. Z.J. Yang, C.E. Chee, S. Huang, F. Sinicrope, Autophagy modulation for cancer therapy. Cancer Biol. Ther. 11, 169-176 (2011)
35. C.H. Cheung, L. Cheng, K.Y. Chang, H.H. Chen, J.Y. Chang, Investigations of survivin: the past, present and future. Front. Biosci. 16, 952-961 (2011)
36. D.M. Vanags, M.I. Porn-Ares, S. Coppola, D.H. Burgess, S. Orrenius, Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J. Biol. Chem. 271, 31075-31085 (1996)
37. R. Nath, K.J. Raser, K. McGinnis, R. Nadimpalli, D. Stafford, K.K. Wang, Effects of ICE-like protease and calpain inhibitors on neuronal apoptosis. Neuroreport 8, 249-255 (1996)
38. R. Nath, K.J. Raser, D. Stafford, I. Hajimohammadreza, A. Posner, H. Allen, R.V. Talanian, P. Yuen, R.B. Gilbertsen, K.K. Wang, Non-erythroid alpha-spectrin breakdown by calpain and interleukin 1 beta-converting-enzyme- like protease(s) in apoptotic cells: contributory roles of both protease families in neuronal apoptosis. Biochem. J. 319, 683-690 (1996)
39. A.M. Di Stasi, V. Gallo, M. Ceccarini, T.C. Petrucci, Neuronal fodrin proteolysis occurs independently of excitatory amino acid-induced neurotoxicity. Neuron 6, 445-454 (1991)
40. D.E. Croall, K. Ersfeld, The calpains: modular designs and functional diversity. Genome Biol. 8, 218 (2007)